Medpace Holdings Dirección

Dirección controles de criterios 4/4

El CEO de Medpace Holdings es August Troendle , nombrado en Jul 1992, tiene una permanencia de 32.33 años. compensación anual total es $1.65M, compuesta por 49.5% salario y 50.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 17.37% de las acciones de la empresa, por valor de MX$37.27B. La antigüedad media del equipo directivo y de la junta directiva es de 5.8 años y 6.3 años, respectivamente.

Información clave

August Troendle

Chief Executive Officer (CEO)

US$1.6m

Compensación total

Porcentaje del salario del CEO	49.5%
Permanencia del CEO	32.3yrs
Participación del CEO	17.4%
Permanencia media de la dirección	5.8yrs
Promedio de permanencia en la Junta Directiva	6.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de August Troendle en comparación con los beneficios de Medpace Holdings?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	US$366m
Jun 30 2024	n/a	n/a	US$340m
Mar 31 2024	n/a	n/a	US$312m
Dec 31 2023	US$2m	US$814k	US$283m
Sep 30 2023	n/a	n/a	US$273m
Jun 30 2023	n/a	n/a	US$268m
Mar 31 2023	n/a	n/a	US$257m
Dec 31 2022	US$2m	US$770k	US$245m
Sep 30 2022	n/a	n/a	US$227m
Jun 30 2022	n/a	n/a	US$209m
Mar 31 2022	n/a	n/a	US$199m
Dec 31 2021	US$6m	US$697k	US$181m
Sep 30 2021	n/a	n/a	US$182m
Jun 30 2021	n/a	n/a	US$175m
Mar 31 2021	n/a	n/a	US$159m
Dec 31 2020	US$4m	US$608k	US$145m
Sep 30 2020	n/a	n/a	US$124m
Jun 30 2020	n/a	n/a	US$107m
Mar 31 2020	n/a	n/a	US$110m
Dec 31 2019	US$8m	US$504k	US$100m
Sep 30 2019	n/a	n/a	US$93m
Jun 30 2019	n/a	n/a	US$88m
Mar 31 2019	n/a	n/a	US$78m
Dec 31 2018	US$528k	US$420k	US$73m
Sep 30 2018	n/a	n/a	US$61m
Jun 30 2018	n/a	n/a	US$52m
Mar 31 2018	n/a	n/a	US$45m
Dec 31 2017	US$598k	US$419k	US$39m

Compensación vs. Mercado: La compensación total de August($USD1.65M) está por debajo de la media de empresas de tamaño similar en el mercado MX ($USD5.75M).

Compensación vs. Ingresos: La compensación de August ha sido consistente con los resultados de la empresa en el último año.

CEO

August Troendle (68 yo)

32.3yrs

Permanencia

US$1,646,031

Compensación

Dr. August James Troendle, M.D. serves as Chairman of CinRx Pharma, LLC. He has been the Chairman, Chief Executive Officer at Medpace Holdings, Inc. since July 1992 and served as its President since July 1...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
August Troendle	Chairman & CEO	32.3yrs	US$1.65m	17.37% MX$ 37.3b
Jesse Geiger	President	3.3yrs	US$945.08k	0.069% MX$ 148.7m
Kevin Brady	CFO & Treasurer	5.8yrs	US$690.48k	0.019% MX$ 41.5m
Susan Burwig	Executive Vice President of Operations	7.8yrs	US$1.12m	0.21% MX$ 449.6m
Stephen Ewald	Chief Compliance Officer	12.4yrs	US$914.64k	0.043% MX$ 92.3m
Brandon Ebken	Chief Information Officer	3.8yrs	sin datos	sin datos
Lauren Morris	Associate Director of Investors Relations	no data	sin datos	sin datos
Todd Meyers	Vice President of Business Development & Marketing	no data	sin datos	sin datos
John Wynne	Senior Vice President of Commercial Operations & Clinical Pharmacology Unit	no data	sin datos	sin datos
Reinilde Heyrman	Chief Medical Officer of Medical Department	1.8yrs	sin datos	sin datos
Gina Leisring	Senior Vice President of Clinical Monitoring	no data	sin datos	sin datos

5.8yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MEDP * es experimentado (5.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
August Troendle	Chairman & CEO	32.3yrs	US$1.65m	17.37% MX$ 37.3b
Fred Davenport	Lead Independent Director	6.3yrs	US$264.98k	0.0065% MX$ 13.8m
Cornelius McCarthy	Independent Director	6.3yrs	US$217.48k	0.017% MX$ 36.1m
Robert Kraft	Independent Director	8.3yrs	US$227.35k	0.0019% MX$ 4.1m
Brian Carley	Independent Director	8.3yrs	US$234.97k	0.070% MX$ 151.0m
Femida Gwadry-Sridhar	Independent Director	1.8yrs	US$258.37k	0% MX$ 0
Dani Zander	Director	less than a year	sin datos	sin datos

6.3yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de MEDP * se considera experimentada (6.3 años de antigüedad promedio).

Medpace Holdings Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Medpace Holdings, Inc., Annual General Meeting, May 17, 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Medpace Holdings, Inc. to Report Q3, 2024 Results on Oct 21, 2024

Second quarter 2024 earnings released: EPS: US$2.85 (vs US$2.00 in 2Q 2023)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Medpace Holdings, Inc. to Report Q2, 2024 Results on Jul 22, 2024

First quarter 2024 earnings released: EPS: US$3.33 (vs US$2.35 in 1Q 2023)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Insufficient new directors

Medpace Holdings, Inc., Annual General Meeting, May 17, 2024

Medpace Holdings, Inc. to Report Q1, 2024 Results on Apr 22, 2024

Insufficient new directors

Medpace Holdings, Inc. Provides Earnings Guidance for the Fiscal Year 2023 and 2024

Medpace Holdings, Inc. to Report Q3, 2023 Results on Oct 23, 2023

Insufficient new directors

Second quarter 2023 earnings released: EPS: US$2.00 (vs US$1.52 in 2Q 2022)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2023

Insufficient new directors

Medpace Holdings, Inc. to Report Q2, 2023 Results on Jul 24, 2023

Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Growth-Defensive Index

Insufficient new directors

First quarter 2023 earnings released: EPS: US$2.35 (vs US$1.76 in 1Q 2022)

Insufficient new directors

Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2023

Insufficient new directors

Medpace Holdings, Inc. to Report Fiscal Year 2022 Results on Feb 13, 2023

Medpace Holdings, Inc. Announces Resignation of Thomas C. King to Board

Insufficient new directors

Insufficient new directors

CFO & Treasurer recently sold Mex$8.8m worth of stock

Insufficient new directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: US$2.13 (vs US$1.35 in 3Q 2021)

Medpace Holdings, Inc. (NasdaqGS:MEDP) announces an Equity Buyback for $500 million worth of its shares.

Insufficient new directors

Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2022 and 2023

Medpace Holdings, Inc. to Report Q3, 2022 Results on Oct 24, 2022

Chairman & CEO recently bought Mex$292m worth of stock

Insufficient new directors

Chairman & CEO recently bought Mex$207m worth of stock

Investor sentiment deteriorated over the past week

Insufficient new directors

Second quarter 2022 earnings released: EPS: US$1.52 (vs US$1.11 in 2Q 2021)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2022

Insufficient new directors

Medpace Holdings, Inc. to Report Q2, 2022 Results on Jul 25, 2022

Insufficient new directors

Insufficient new directors

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2022

Medpace Holdings, Inc., Annual General Meeting, May 20, 2022

Investor sentiment deteriorated over the past week

Lead Independent Director recently bought Mex$1.5m worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Medpace Holdings, Inc. Provides Consolidated Earnings Guidance for the Year 2022

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS US$1.36 (vs US$1.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS US$1.11 (vs US$0.68 in 2Q 2020)

Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2021

Executive Vice President of Operations recently sold Mex$22m worth of stock

Medpace Holdings, Inc. to Report Q1, 2021 Results on Apr 26, 2021

Executive Vice President of Operations recently sold Mex$22m worth of stock

Full year 2020 earnings released: EPS US$4.07 (vs US$2.79 in FY 2019)

Revenue beats expectations

Investor sentiment improved over the past week

Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Dynamic Index

Medpace Holdings, Inc. to Report Q4, 2020 Results on Feb 15, 2021

Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from S&P 600 Health Care (Sector)

Medpace Holdings, Inc. to Report Q3, 2020 Results on Oct 26, 2020

Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Dynamic Index

Análisis de compensación del CEO